Bill & Melinda Gates Foundation

Micron Biomedical is a clinical-stage biopharmaceutical company founded in 2014 and based in Atlanta, Georgia. The company focuses on developing innovative microneedle patches designed for administering vaccines, specifically targeting influenza and polio. Its proprietary microneedle technology aims to enhance the protective and therapeutic effects of vaccines while improving patient compliance and simplifying the administration process. Through its advanced delivery methods, Micron Biomedical seeks to facilitate the development of vaccines that can address critical healthcare needs.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

Micron Biomedical is a clinical-stage biopharmaceutical company founded in 2014 and based in Atlanta, Georgia. The company focuses on developing innovative microneedle patches designed for administering vaccines, specifically targeting influenza and polio. Its proprietary microneedle technology aims to enhance the protective and therapeutic effects of vaccines while improving patient compliance and simplifying the administration process. Through its advanced delivery methods, Micron Biomedical seeks to facilitate the development of vaccines that can address critical healthcare needs.

Osmo is a company that develops an artificial intelligence platform designed to give computers a sense of smell. By combining advanced AI with olfactory science, Osmo addresses significant challenges in the fragrance industry while also aiming to enhance human health and well-being. The company creates aroma molecules for a variety of products, including perfumes, shampoos, lotions, and candles. Additionally, Osmo's technology has the potential to detect diseases earlier and track pandemics, thereby improving consumer experience and overall wellness. Through its innovative approach, Osmo seeks to transform the way scent is integrated into everyday life and contribute positively to public health.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

Latham BioPharm Group is a firm specializing in life sciences, offering comprehensive expertise in business development, program management, quality assurance, regulatory affairs, and strategic consulting. With a team that boasts an average of over 20 years of experience, including roles as senior executives in both startups and Fortune 200 companies, Latham BioPharm has a strong foundation in guiding clients through the complexities of product development. The company has a proven track record in biodefense and pandemic response, having successfully assisted clients in identifying and securing funding, managing programs, and monetizing opportunities across various sectors. Their services include strategy and portfolio analysis, market research, and connecting clients with target markets to enhance decision-making. Latham BioPharm's expertise has contributed to generating substantial government funding and licensing fees, positioning them as a key partner in advancing innovations in vaccines, therapeutics, medical devices, and diagnostics.

Noze is a pioneering company in digital odor perception, recognized for creating an advanced digital nose that accurately detects and identifies odors in various real-world contexts. Leveraging cutting-edge machine perception technology and a specialized sensor developed from NASA innovations, Noze aims to enhance human health and wellbeing. The company's technology mimics the human olfactory system, allowing it to gather data on air quality and chemical footprints based on scent. This enables healthcare providers to monitor and predict health changes, diagnose diseases, and perform routine screenings through breath-based odor biomarkers. Ultimately, Noze is dedicated to facilitating real-time disease detection at any point-of-care, thereby significantly improving patient outcomes.

MIP Discovery is a technology leader specializing in the development of Molecularly Imprinted Polymers (MIPs) and nanoMIPs, which are plastic antibodies designed to overcome the limitations of conventional MIP manufacturing. The company focuses on creating polymers and antibodies that feature a single binding site for specific targets, allowing them to be integrated with solid substrates, such as sensor surfaces. This innovation enables MIP Discovery to provide ideal reagents for various applications, including point-of-care diagnostics and field-based testing, making significant contributions to the healthcare and diagnostics sectors.

Osmo is a company that develops an artificial intelligence platform designed to give computers a sense of smell. By combining advanced AI with olfactory science, Osmo addresses significant challenges in the fragrance industry while also aiming to enhance human health and well-being. The company creates aroma molecules for a variety of products, including perfumes, shampoos, lotions, and candles. Additionally, Osmo's technology has the potential to detect diseases earlier and track pandemics, thereby improving consumer experience and overall wellness. Through its innovative approach, Osmo seeks to transform the way scent is integrated into everyday life and contribute positively to public health.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

ExploRNA Therapeutics is focused on advancing messenger ribonucleic acid (mRNA) as a therapeutic platform for anti-cancer applications and vaccinations. The company develops innovative therapeutics by modifying the cap structure of mRNA, which enhances its stability and translation efficiency. This technology enables the medical community to stimulate adaptive immune responses, ultimately aiming to improve treatment outcomes for patients. ExploRNA Therapeutics collaborates with pharmaceutical partners to implement its ideas into distinct therapeutic programs, providing both technology and medications that address critical health challenges. Through its cutting-edge research and development efforts, the company is positioned to make significant contributions to the field of mRNA therapeutics.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Ilara Health is a company based in Nairobi, Kenya, founded in 2018, that specializes in the development and distribution of AI-powered diagnostic devices aimed at primary care doctors in peri-urban and rural clinics. The company's innovative technology platform integrates miniature diagnostic devices with software that connects to an electronic medical record system, allowing healthcare providers to efficiently manage patient data. By focusing on accurate and affordable diagnostics, Ilara Health seeks to enhance healthcare accessibility and quality for rural populations in Africa, addressing the challenges posed by a fragmented healthcare infrastructure.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

PiQuant specializes in advanced sensor technology based on spectroscopy, offering solutions for component detection at a molecular level. Its high-sensitivity sensors, which are compact and affordable, enable a range of applications including air monitoring, portable water quality assessment, and skin condition analysis. The company aims to provide accurate quantitative analysis through its mini-spectrometer technology, making it accessible for various sectors such as smart homes, smart cities, smart factories, smart farms, and healthcare. By focusing on affordability and size, PiQuant seeks to enhance the capabilities of users while promoting the integration of its innovative technology into everyday environments.

Credence MedSystems, Inc. is a specialty pharmaceutical and drug delivery company based in Menlo Park, California. Established in 2011 and formerly known as SafeShot Technologies, the company focuses on developing innovative injectable drug delivery systems aimed at enhancing patient and caregiver safety. Its flagship products include the Companion Staked Needle Syringe, Companion Luer Syringe, and Companion Dual Chamber Reconstitution Safety Syringe, as well as the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable design for single-use applications. Credence MedSystems collaborates with SCHOTT AG to advance its technology, which emphasizes passive needle safety and reuse prevention, enabling a smoother commercialization process for pharmaceutical partners while minimizing risks associated with injection practices.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular platform, compatible with standard lab processes, aims to simplify blood sampling for both patients and healthcare professionals, making it more accessible and convenient. The technology, supported by Qloudlab's expertise in connected devices and biosensors, is designed to enhance healthcare outcomes by improving the blood collection process.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Evolve Biosystems, Inc. is a life sciences company based in Davis, California, that focuses on developing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. Incorporated in 2011, the company utilizes a discovery platform that addresses dysbiosis issues throughout the human life cycle and in production animals. Evolve Biosystems specializes in probiotic bacteria activated with specific prebiotic oligosaccharides and employs various delivery systems to support gut health, particularly in infants during their first six months of life. Their product offerings include consumer-directed solutions for home use as well as specialized products for neonatal intensive care units, addressing unmet clinical needs in both human and animal health.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular platform, compatible with standard lab processes, aims to simplify blood sampling for both patients and healthcare professionals, making it more accessible and convenient. The technology, supported by Qloudlab's expertise in connected devices and biosensors, is designed to enhance healthcare outcomes by improving the blood collection process.

Danforth Technology Company (DTC) is a venture builder based in St. Louis, Missouri, and operates as a subsidiary of the Donald Danforth Plant Science Center. Its primary role is to facilitate the early-stage development of startup companies that leverage technologies developed by the Center's scientists. DTC focuses on moving scientific discoveries into the marketplace more efficiently by providing intellectual property development, licensing, and entrepreneurship support. The company also offers seed funding and early management assistance to promising startups, enhancing the potential for innovation in plant science and contributing to broader societal goals such as improving human health and environmental sustainability.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Atomo Diagnostics is an Australian company specializing in the research, design, development, and manufacture of medical devices for blood-based rapid testing, catering to both professional and consumer markets. Established in 2010 and headquartered in Leichhardt, Australia, the company offers its AtomoRapid RDT platforms, which are designed for a variety of blood-based lateral flow test assays. These devices are capable of screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics distinguishes itself by focusing on usability and user experience, addressing existing challenges in rapid diagnostic testing (RDT) through innovative design and patented features. This approach aims to enhance safety, accuracy, and reliability while minimizing user error. The company has a global presence, with operations in Europe, Asia, Africa, and Central and South America, and is led by an experienced management team dedicated to commercializing disruptive healthcare products.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Sure Chill is a company specializing in innovative cooling technology that operates without a power source. By utilizing the unique properties of water, it provides continuous cooling at a consistent temperature of 4ºC, making it suitable for various environments worldwide. Since its introduction to the medical market in 2011, Sure Chill's vaccine refrigerators have surpassed the stringent standards of the World Health Organization and are utilized by organizations such as UNICEF to protect vaccines and save lives in 46 countries. The technology is particularly beneficial in developing countries, enhancing vaccine delivery and maintaining the integrity of essential medicines and food in areas with unreliable electricity. Sure Chill's advancements in the cold chain have garnered recognition, including a significant award from the Bill and Melinda Gates Foundation to further improve vaccine distribution.

Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.

Sure Chill is a company specializing in innovative cooling technology that operates without a power source. By utilizing the unique properties of water, it provides continuous cooling at a consistent temperature of 4ºC, making it suitable for various environments worldwide. Since its introduction to the medical market in 2011, Sure Chill's vaccine refrigerators have surpassed the stringent standards of the World Health Organization and are utilized by organizations such as UNICEF to protect vaccines and save lives in 46 countries. The technology is particularly beneficial in developing countries, enhancing vaccine delivery and maintaining the integrity of essential medicines and food in areas with unreliable electricity. Sure Chill's advancements in the cold chain have garnered recognition, including a significant award from the Bill and Melinda Gates Foundation to further improve vaccine distribution.

YourBio Health is focused on transforming the blood sampling and testing process by creating innovative products that enhance the interface between diagnostic medicine and healthcare consumers. The company has developed a unique blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy technology, this push-button device can be applied to the upper arm, enabling individuals to collect their blood with a simple press of a button. This one-step process is designed to eliminate barriers to acquiring critical diagnostic information, facilitating improved diagnoses and health outcomes. By making diagnostic testing accessible almost anywhere, YourBio Health aims to empower patients in their healthcare journey and enhance the overall experience for both patients and clinicians.